Obecne postępowanie w zwyrodnieniu plamki związanym z wiekiem (AMD) i retinopatii cukrzycowej (DR)

• Authors: Stankiewicz Andrzej
• Languages of publication: PL

Keywords

PL

zwyrodnienie plamki związane z wiekiem (AMD); retinopatia cukrzycowa (DR); leczenie anty-VEGF; fotokoagulacja laserowa

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2012
• Issue: 3
• Pages: 501-506

Contributors

author

Stankiewicz Andrzej

References

• Stankiewicz A, Figurska M. Zwyrodnienie plamki związane z wiekiem. Poznań: Wydawnictwo Medyczne Termedia;2010.
• Muzyka-Woźniak M, Misiuk-Hojlo M, Wesłowska A. Jakość życia chorych na zwyrodnienie plamki związane z wiekiem – problem medyczny i społeczny. Klin Oczna 2011; 113: 161−164.
• The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
• Klein R, Klein B, Marino B, et al. Early age-related maculopathy in Cardiovascular Health Study. Ophthalmology 2003;110: 25−33.
• Stankiewicz A. Zwyrodnienie plamki związane z wiekiem (AMD) − wstępne wyniki akcji „Bus-Tour” 2011. Klin Oczna 2011; 113: 341−345.
• Figurska M, Wierzbowska J, Robaszkiewicz J. Combined therapy in exudative age-related macular degeneration. Klin Oczna 2010; 112: 223−229.
• Ip M, Scott I, Brown G, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration. Ophthalmology 2008; 115: 1827−1835.
• Michael I, Scott I, Gary C, et al. Anti-vascular endothelial growth factor pharmacotherapy for Age-Related Macular Degeneration. A report by American Academy of Ophthalmology. Ophthalmology 2008; 115: 1837−1842.
• Ozaki H, Hayashi H, Vinores S, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and primates. Exp Eye Res 1997; 64: 505−517.
• Boyer D, Heir J, Brown D, et al. A phase III b study to evaluate the safety of ranibizumab in subject with neovascular age-related macular degeneration. Ophthalmology 2009; 116: 1731−1739.
• Mitchell P, Korbelnik J, Lanzetta P, et al. Ranbizumab (Lucentis) in neovascular age- related macular degeneration.Evidence from clinical trials. Br J Ophthalmol 2010; 94: 2−13.
• Brechner R, Rosenfeld P, Babish J, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File. Am J Ophthalmol 2011; 151: 887−895.
• Curtis L. Hammill B, Schuman K, et al. Risk of mortality, myocardial infarction, bleeding and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128: 1273−1279.
• Carneiro A, Barthelmes D, Falcao M, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011; 225: 211−221
• Stewart M, Rosenfeld P. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 667−668.
• Brown D, Heir J, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor Trap-Eye in wet age-related macular degeneration. Ophthalmology 2011; 118: 1089−1097.
• Wilczyński M, Omulecki W. Zarys patogenezy retinopatii cukrzycowej Warszawa: Wydawnictwo Medyczne Oftal;2007.
• Mitchel P, Bandello F, Schmidt-Erfarth U, et al. The RESTORE study. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615−625.
• Massin P, Bandello F, Garweg J, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOVE Study). Diab Care 2010; 11: 2399−2405.
• Nguyen Q, Shah S, Heir J, et al. Primary end point (six month) results of ranibizumab for edema of macula; diabetes (READ-2) study. Ophthalmology 2009; 116: 2175−2181.
• Nguyen Q, Shah S, Khwaya A, et al. Two-year outcomes of ranibizumab for edema of macula in diabetes.Ophthalmology 2010; 117: 2146−215